Tumor necrosis factor alpha antagonists (e.g. etanercept) are now being extensively evaluated in the setting of chronic wound healing. Preliminary studies and case reports provide evidence of the clinical potential of these compounds in pyoderma gangrenosum, and further investigations are warranted. A clear rationale also exists for further detailed assessments of the potential efficacy of etanercept in patients with venous leg ulcers or hospital-acquired pressure ulcers.
|Original language||English (US)|
|Number of pages||3|
|Journal||American Journal of Clinical Dermatology|
|Issue number||SUPPL. 1|
|State||Published - Jul 9 2010|
ASJC Scopus subject areas